pharmaphorum
APRIL 26, 2024
In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and manufacturing operations.
Bio Pharma Dive
APRIL 26, 2024
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition that were approved earlier struggle to gain traction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
APRIL 26, 2024
The paper identifies the roles of LARP4A and LARP4B in sarcoma and carcinoma cancers
Bio Pharma Dive
APRIL 26, 2024
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharma Times
APRIL 26, 2024
The new method could help to prevent severe side effects caused by enantiomer drugs
Pharmaceutical Technology
APRIL 26, 2024
The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
APRIL 26, 2024
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.
pharmaphorum
APRIL 26, 2024
Explore the latest advancements and initiatives in kidney disease research, driving change for patients with kidney conditions. Learn more about the current research landscape and potential breakthroughs in treatment from Kidney Research UK.
Pharmaceutical Technology
APRIL 26, 2024
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.
pharmaphorum
APRIL 26, 2024
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
APRIL 26, 2024
The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.
Fierce Pharma
APRIL 26, 2024
After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition. | After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. With a busy year ahead across therapeutic areas, CEO Dan O'Day emphasized a "time of focused execution.
Pharmaceutical Technology
APRIL 26, 2024
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing.
pharmaphorum
APRIL 26, 2024
Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.
Pharmaceutical Technology
APRIL 26, 2024
Merck has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in Q1 2024, a 69% rise from $2.82bn in the same period last year.
Pharmaceutical Commerce
APRIL 26, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
APRIL 26, 2024
AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year.
Fierce Pharma
APRIL 26, 2024
GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots fkansteiner Fri, 04/26/2024 - 10:07
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
APRIL 26, 2024
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
Drug Channels
APRIL 26, 2024
Today’s guest post comes from Kevin Kettler, President of CoverMyMeds. Kevin asks: What if there were no barriers across the therapy access and reimbursement process? In his view, eliminating barriers requires a combination of expert insight, actionable data, and simplification of the providers' experiences. Click here to learn more about CoverMyMeds’ comprehensive technology solutions.
Fierce Pharma
APRIL 26, 2024
AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. | As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis.
pharmaphorum
APRIL 26, 2024
Merino Perugini from Nestlé Health Science sat down for an exclusive interview with Jonah Comstock from Reuters Pharma USA to discuss the company's latest innovations and successes in the healthcare industry. Get insights into their strategies and future plans.
Outsourcing Pharma
APRIL 26, 2024
In an extensive and enlightening chat with Prasad Rajeev, the CEO of LGM Pharma, OSP gained profound insights into the company's trajectory within the pharmaceutical industry.
Drug Patent Watch
APRIL 26, 2024
This chart shows the drugs with the most patents in South Africa.
Fierce Pharma
APRIL 26, 2024
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atop | For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown better skin clearance than Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD).
Drug Patent Watch
APRIL 26, 2024
Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from three suppliers.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
APRIL 26, 2024
There is no doubt that drug shortages are a detriment to the pharma supply chain, but how commonplace were they during the COVID era?
Drug Patent Watch
APRIL 26, 2024
Annual Drug Patent Expirations for XOSPATA Xospata is a drug marketed by Astellas and is included in one NDA. It is available from one supplier.
pharmaphorum
APRIL 26, 2024
Gain insights into market access strategies for 2024 with a deep dive featuring perspectives from industry leaders such as Alexion, Putnam, Inizio Advisory, and insights from Reuters Pharma US.
Drug Patent Watch
APRIL 26, 2024
Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. It is available from one supplier.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
111 
Let's personalize your content